JPWO2020106843A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020106843A5
JPWO2020106843A5 JP2021527959A JP2021527959A JPWO2020106843A5 JP WO2020106843 A5 JPWO2020106843 A5 JP WO2020106843A5 JP 2021527959 A JP2021527959 A JP 2021527959A JP 2021527959 A JP2021527959 A JP 2021527959A JP WO2020106843 A5 JPWO2020106843 A5 JP WO2020106843A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
engineered
cells
proteins
exogenous polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021527959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507830A (ja
JP2022507830A5 (https=
Publication date
Priority claimed from US16/445,965 external-priority patent/US10918667B2/en
Application filed filed Critical
Priority claimed from PCT/US2019/062417 external-priority patent/WO2020106843A1/en
Publication of JP2022507830A publication Critical patent/JP2022507830A/ja
Publication of JPWO2020106843A5 publication Critical patent/JPWO2020106843A5/ja
Publication of JP2022507830A5 publication Critical patent/JP2022507830A5/ja
Pending legal-status Critical Current

Links

JP2021527959A 2018-11-20 2019-11-20 治療薬を発現する改変細胞とその使用 Pending JP2022507830A (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201862769987P 2018-11-20 2018-11-20
US62/769,987 2018-11-20
US201862774595P 2018-12-03 2018-12-03
US62/774,595 2018-12-03
US201962795810P 2019-01-23 2019-01-23
US62/795,810 2019-01-23
US201962828770P 2019-04-03 2019-04-03
US62/828,770 2019-04-03
US201962846563P 2019-05-10 2019-05-10
US62/846,563 2019-05-10
US201962848961P 2019-05-16 2019-05-16
US62/848,961 2019-05-16
US16/445,965 US10918667B2 (en) 2018-11-20 2019-06-19 Modified cell expressing therapeutic agent and uses thereof
US16/445,965 2019-06-19
US201962889926P 2019-08-21 2019-08-21
US62/889,926 2019-08-21
US201962902766P 2019-09-19 2019-09-19
US62/902,766 2019-09-19
PCT/US2019/062417 WO2020106843A1 (en) 2018-11-20 2019-11-20 Modified cell expressing therapeutic agent and uses thereof

Publications (3)

Publication Number Publication Date
JP2022507830A JP2022507830A (ja) 2022-01-18
JPWO2020106843A5 true JPWO2020106843A5 (https=) 2022-11-29
JP2022507830A5 JP2022507830A5 (https=) 2022-11-29

Family

ID=70774027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021527959A Pending JP2022507830A (ja) 2018-11-20 2019-11-20 治療薬を発現する改変細胞とその使用

Country Status (7)

Country Link
US (2) US20220000921A1 (https=)
EP (1) EP3883585A4 (https=)
JP (1) JP2022507830A (https=)
AU (1) AU2019384145A1 (https=)
CA (1) CA3120153A1 (https=)
SG (1) SG11202105173VA (https=)
WO (1) WO2020106843A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
EP3810640A1 (en) * 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
WO2020028275A1 (en) * 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
JP7156653B2 (ja) 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス,エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
EP3883956A1 (en) 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
JP2022531814A (ja) * 2019-03-12 2022-07-12 イノベイティブ セルラー セラピューティクス ホールディングス,エルティディ 改変細胞の増幅およびその応用
AU2020315800A1 (en) 2019-07-19 2022-03-03 Seneca Therapeutics, Inc. Second generation seneca valley virus oncolytic therapy: compositions and methods thereof
US20210060069A1 (en) * 2019-08-23 2021-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Coupled redirected cells and uses thereof
BR112022009110A2 (pt) * 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
WO2021179967A1 (zh) * 2020-03-09 2021-09-16 四川大学华西医院 IFN-γ在制备抗肿瘤辅助药物中的应用
EP3892720A1 (en) 2020-04-06 2021-10-13 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
KR20230040364A (ko) * 2020-07-27 2023-03-22 센터 포 엑설런스 인 몰레큘러 셀 사이언스, 차이니즈 아카데미 오브 사이언시스 키메라 항원 수용체 및 이의 용도
WO2022038264A1 (en) * 2020-08-21 2022-02-24 Julius-Maximilians-Universität Würzburg Modified lymphocytes
JP2023545126A (ja) * 2020-10-12 2023-10-26 武田薬品工業株式会社 Car-t細胞の細胞動態及び体内分布の決定
WO2022159508A1 (en) * 2021-01-19 2022-07-28 Seneca Therapeutics, Inc. Armed seneca valley virus oncolytic therapy compositions and methods thereof
US11633427B2 (en) * 2021-02-05 2023-04-25 Innovative Cellular Therapeutics Holdings, Ltd. Vaccine and uses thereof in cell therapy
CN113046320B (zh) * 2021-02-19 2023-04-14 中国医学科学院基础医学研究所 胞外段为Vδ1(GTM)Vγ4的CAR分子及表达该分子的CAR-T细胞及其用途
CN114934071B (zh) * 2021-04-30 2023-10-17 四川大学华西医院 一种表达免疫调节因子的car载体及其应用
EP4215245A1 (en) 2022-01-19 2023-07-26 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment
AU2024289944A1 (en) 2023-07-05 2026-01-29 Nanotein Technologies, Inc. Cell signaling complexes and uses thereof
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
WO2025117789A1 (en) * 2023-12-01 2025-06-05 Parker Institute For Cancer Immunotherapy Engineered immune signaling constructs
WO2025184170A1 (en) 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment
WO2025184172A1 (en) * 2024-02-27 2025-09-04 Overt Bio, Inc. Cancer reactive t cell receptors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508878A (en) * 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1572242B1 (en) * 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2010081738A1 (en) * 2009-01-16 2010-07-22 Agirx Limited Vaccine compositions
AU2010241864B2 (en) * 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
AU2011239569B2 (en) * 2010-04-16 2014-07-24 Baylor College Of Medicine Method for treating solid tumors
EP2640404B1 (en) * 2010-11-17 2017-02-22 Ben Gurion University of The Negev Research and Development Authority T-cell therapy to neurodegenerative diseases
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9402865B2 (en) * 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
AU2012267710A1 (en) * 2011-06-08 2014-01-23 The Regents Of The University Of California Anti-CD22 antigen binding molecules to treat lung cancer and prostate cancer
WO2013059593A1 (en) * 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
US11382963B2 (en) * 2015-01-12 2022-07-12 Pieris Pharmaceuticals Gmbh Engineered T cells and uses therefor
US10493139B2 (en) * 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
CN108243607A (zh) * 2015-09-09 2018-07-03 西雅图儿童医院(Dba西雅图儿童研究所) 用于免疫疗法的巨噬细胞的遗传工程
JP7115982B2 (ja) * 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド 癌の治療のための組成物及び方法
AU2017225733A1 (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
CN109219445B (zh) * 2016-04-01 2022-08-26 上海煦顼技术有限公司 嵌合抗原受体修饰细胞治疗癌症的应用
US11377637B2 (en) * 2016-04-15 2022-07-05 Memorial Sloan Kettering Cancer Center Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
WO2017186121A1 (zh) * 2016-04-26 2017-11-02 科济生物医药(上海)有限公司 一种改善免疫应答细胞功能的方法
WO2018064921A1 (en) * 2016-10-06 2018-04-12 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
WO2018136566A1 (en) * 2017-01-18 2018-07-26 F1 Oncology, Inc. Methods of transducing and expanding immune cells and uses thereof
US10561686B2 (en) * 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof

Similar Documents

Publication Publication Date Title
JPWO2020106843A5 (https=)
JP2019525956A5 (https=)
HRP20251135T1 (hr) Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore
JP2017513818A5 (https=)
JP2021532742A5 (https=)
US11564945B2 (en) Chimeric antigen receptor and use thereof
IL295604A (en) Methods of making chimeric antigen receptor-expressing cells
JP2021520788A5 (https=)
JP2019516350A5 (https=)
JP2021534783A5 (https=)
JP2019513347A5 (https=)
CA3102641A1 (en) Chimeric transmembrane proteins and uses thereof
RU2019133286A (ru) Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью
JP2019518424A5 (https=)
JP2020506700A5 (https=)
JP2017504601A5 (https=)
JPWO2022183072A5 (https=)
IL297514A (en) Vectors and methods for in vivo transduction
CN111542545A (zh) Cd38定向嵌合抗原受体构建体
JPWO2021173985A5 (https=)
JPWO2019200007A5 (https=)
JP2021530233A5 (https=)
US20230257477A1 (en) Dual chimeric antigen receptor t cells targeting ccd99- and clec12a-expressing cancers
CN117683139A (zh) 组成型嵌合细胞因子受体及表达其的免疫细胞及应用
JPWO2020020359A5 (https=)